THE CHROMOSOME | Clinical Content Series
DHEA Imbalance
Back to Case Studies ArchiveCase Study
He was 47 years old and described himself as having aged a decade in three years. Not in the way people say this casually, as a figure of speech for feeling tired or overworked, but in the precise, biological sense of a man whose physical vitality, cognitive sharpness, hormonal resilience, and metabolic efficiency had deteriorated across a three year period with a speed and completeness that felt entirely disproportionate to his chronological age. He had gained 24 kilograms. He had lost muscle from every part of his body except his abdomen, which had expanded steadily. His immune system had become unreliable, he was catching infections that his body had previously resisted without effort, and recovering from them slowly when previously he had recovered quickly. His sleep was disturbed and unrefreshing. His memory had become less reliable in ways that troubled him professionally. His resilience to stress, which had once been one of the qualities he most valued in himself, had diminished to the point where situations he would previously have navigated with composure were producing anxiety, irritability, and a sense of being overwhelmed that was entirely foreign to his experience of himself.
He had been told he was burned out. He had been told he needed rest. He had been told that what he was describing was the inevitable consequence of the professional demands he had placed on himself across a high pressure career.
None of these explanations were wrong. But none of them were complete. And none of them were actionable in the way that a hormonal diagnosis is actionable, because burned out is a description, not a treatment, and rest addresses the circumstances without touching the biological machinery that chronic stress had dismantled.
When I evaluated his complete hormonal profile alongside the standard metabolic assessment, one finding stood out with particular clarity. His DHEA-S, dehydroepiandrosterone sulphate, the circulating storage form of DHEA, was at 58 micrograms per decilitre. For a man of his age the reference range extends from 80 to 560. His DHEA was not simply low. It was critically, severely depleted, at a level I associate with patients in their late sixties and seventies rather than a man in his mid forties.
DHEA, dehydroepiandrosterone, is the most abundant steroid hormone in the human body and one of the least understood in Pakistani clinical medicine, which is to say it is almost entirely unrecognised and almost never measured. It is produced predominantly by the adrenal glands, with additional production in the gonads and brain, and it serves as the primary precursor from which testosterone and oestrogen are synthesised in peripheral tissues, the hormonal raw material from which the body manufactures the sex hormones it needs, in the tissues that need them, at the time they need them. Beyond its role as a precursor, DHEA exerts its own direct biological effects, on immune function, on cognitive performance, on mood regulation, on bone density, on cardiovascular health, on insulin sensitivity, and on the body's capacity to manage stress without physiological deterioration.
DHEA production peaks in the mid twenties and declines progressively with age, by approximately two percent annually through the adult decades. This age related decline is universal. What is not universal, and what Pakistani clinical medicine never measures and therefore never identifies, is the pathologically accelerated DHEA decline that chronic stress, visceral obesity, insulin resistance, cortisol excess, and the FTO associated metabolic predisposition produce in Pakistani patients who are, by their biology, predisposed to adrenal depletion under the sustained stress burden of Pakistani professional and family life.
The relationship between DHEA and cortisol is one of the most clinically important hormonal dynamics I evaluate in Pakistani patients. DHEA and cortisol are produced by the same adrenal cells from the same precursor, pregnenolone, and they exist in a balance that reflects the adrenal gland's current allocation of its biosynthetic resources. Under conditions of chronic stress, the adrenal gland consistently prioritises cortisol production, directing the available pregnenolone toward cortisol synthesis at DHEA's expense. The result is the pattern I find consistently in Pakistani patients with chronic stress exposure and adrenal dysregulation, elevated or dysregulated cortisol alongside severely depleted DHEA, a hormonal combination that produces accelerated biological ageing, immune suppression, cognitive decline, insulin resistance, and the progressive loss of hormonal resilience that this patient was experiencing with such clinical precision.
His cortisol pattern was significantly dysregulated, confirming the adrenal allocation I had expected. His testosterone was low for his age, reflecting both the DHEA depletion that had reduced his androgenic precursor supply and the visceral fat aromatisation that was converting his residual testosterone to oestrogen. His insulin resistance was significant. His growth hormone axis was impaired. His inflammatory markers were elevated. His vitamin D was severely deficient. Every finding was consistent with a man whose adrenal biosynthetic capacity had been overwhelmed by sustained cortisol demand, leaving DHEA critically depleted and every hormonal system that depended on adequate DHEA supply operating in deficit.
The FTO gene's influence on DHEA in Pakistani patients operates through its promotion of the visceral fat accumulation, insulin resistance, and chronic inflammatory environment that accelerate adrenal DHEA depletion independently of age. The FTO associated metabolic profile creates a baseline of chronic low grade inflammation and metabolic stress that places a sustained biosynthetic demand on the adrenal glands, gradually depleting DHEA as cortisol production is chronically prioritised. Pakistani patients with the FTO associated metabolic profile experience DHEA depletion that is earlier in onset, more severe in degree, and more clinically consequential than the age related decline that Western clinical models describe, yet DHEA is almost never measured in Pakistani clinical practice because its clinical significance is not taught, its measurement is not standard, and its treatment, where indicated, requires a level of hormonal sophistication that most Pakistani physicians have never been trained to provide.
We addressed his DHEA depletion as part of a comprehensive hormonal restoration strategy. We treated his cortisol dysregulation, reducing the adrenal allocation to cortisol that had been depleting his DHEA precursor supply. We reduced his visceral fat and treated his insulin resistance, removing the inflammatory and metabolic stress that had been sustaining the cortisol demand. We restored his sleep architecture, because sleep is the primary period of adrenal recovery and DHEA synthesis restoration. We supported his testosterone through the combined effects of DHEA precursor restoration and the direct hormonal interventions appropriate to his degree of deficiency. We addressed his vitamin D deficiency. We optimised his growth hormone axis. Where direct DHEA supplementation was clinically indicated within this comprehensive framework, it was incorporated precisely and monitored carefully.
Fifteen months later his DHEA-S had risen to 187 micrograms per decilitre, substantially restored toward the optimal range for his age. He had lost 21 kilograms. His muscle had returned. His immune resilience had recovered, he had not had a single significant infection across the final nine months of treatment. His sleep had transformed. His cognitive sharpness had returned to a level he described as sharper than it had been before the deterioration began. His stress resilience had recovered in a way that he described, with some surprise, as feeling protected from the inside rather than simply better rested.
He had not been burned out. He had been hormonally depleted, specifically, adrenally depleted in the DHEA dimension that nobody had ever thought to measure. And hormonal depletion, unlike burnout, has a precise biological solution.
FAQs
Dehydroepiandrosterone, DHEA, is the most abundant steroid hormone in the human body, produced predominantly by the adrenal glands and serving as the primary precursor from which testosterone and oestrogen are synthesised in peripheral tissues. Beyond its precursor role, DHEA exerts direct biological effects on immune function, cognitive performance, mood regulation, insulin sensitivity, bone density, cardiovascular health, and stress resilience. Despite this broad biological importance, DHEA is almost never measured in Pakistani clinical practice, because it is not taught as a clinically significant hormone in Pakistani medical training, it is not included in standard hormonal or metabolic panels, and its relationship to the obesity, fatigue, immune suppression, and cognitive decline it produces in deficient Pakistani patients is never considered in the differential diagnosis of these conditions.
DHEA and cortisol are produced from the same precursor, pregnenolone, by the same adrenal cells. Under conditions of chronic stress, the adrenal glands consistently prioritise cortisol synthesis, directing the available pregnenolone toward cortisol at DHEA's expense. In Pakistani patients exposed to the sustained professional, familial, and social stress burdens that characterise Pakistani urban life, this chronic cortisol prioritisation progressively depletes DHEA over months and years, producing a hormonal combination of dysregulated cortisol and critically low DHEA that accelerates biological ageing, suppresses immune function, deepens insulin resistance, reduces testosterone precursor availability, impairs cognitive function, and removes the stress resilience that adequate DHEA provides. This pattern is present in a substantial proportion of the Pakistani patients Dr. Zaar evaluates comprehensively, and is never identified in those who receive only standard metabolic panels.
The FTO gene at Chromosome 16q12.2 promotes the visceral fat accumulation, insulin resistance, and chronic low grade inflammation that place sustained biosynthetic demand on the adrenal cortisol production system, gradually depleting DHEA as cortisol is chronically prioritised to manage the metabolic stress the FTO associated profile generates. Pakistani patients with significant visceral obesity and the FTO associated metabolic predisposition experience DHEA depletion that is earlier in onset and more severe in degree than the age related decline that Western clinical models describe as normal. The visceral inflammatory cytokines that the FTO associated fat accumulation generates directly impair adrenal DHEA synthesis independently of cortisol competition, adding an additional depletion mechanism to the cortisol pregnenolone competition that chronic stress produces simultaneously.
DHEA exerts direct anti-obesity effects through multiple simultaneous mechanisms, it inhibits the enzyme glucose-6-phosphate dehydrogenase that supports lipid synthesis in fat cells, it promotes fat oxidation by supporting mitochondrial function, it opposes the fat storing effects of cortisol through direct competitive antagonism at the glucocorticoid receptor level, and it supports the insulin sensitivity that prevents the compensatory hyperinsulinaemia driving visceral fat storage. When DHEA is severely depleted, all of these anti-obesity effects are simultaneously removed, leaving the fat storing, metabolically suppressive effects of cortisol unopposed and the insulin resistance that drives visceral fat accumulation unsupported by the insulin sensitising influence that adequate DHEA provides. In Pakistani patients, where cortisol dysregulation is prevalent and insulin resistance is the primary metabolic driver, DHEA depletion removes the biological counterbalance that might otherwise moderate both.
DHEA is one of the most important regulators of immune function in human physiology, it supports the T helper cell balance that discriminates between appropriate immune responses and inappropriate autoimmune or inflammatory activation, promotes natural killer cell activity that provides protection against viral infection and malignant cell development, and modulates the cytokine environment that determines whether the immune response is appropriately calibrated or chronically dysregulated. In Pakistani patients with severe DHEA depletion, immune function deteriorates across multiple dimensions simultaneously, increasing susceptibility to infections that a DHEA replete immune system would resist, promoting the autoimmune dysregulation that drives Hashimoto's and other autoimmune conditions, and deepening the chronic inflammatory state that perpetuates every other metabolic disorder. The pattern of frequent infections, slow recovery, and autoimmune susceptibility that DHEA depleted Pakistani patients describe is a direct consequence of lost immune regulation, and it resolves with DHEA restoration.
DHEA is produced directly in the brain, where it is classified as a neurosteroid, and exerts significant effects on cognitive performance, mood regulation, and stress resilience through its modulation of GABA and NMDA receptor activity, its support of neuronal growth factor production, and its direct influence on the hippocampal function that governs memory, learning, and emotional regulation. DHEA deficiency in Pakistani patients produces a cognitive profile of reduced working memory, impaired processing speed, decreased stress tolerance, and motivational flatness that Pakistani physicians attribute to burnout, depression, or cognitive ageing without measuring the neurosteroid whose depletion is producing these consequences. The mood consequences, anxiety, irritability, emotional fragility, and the loss of psychological resilience, are similarly attributed to circumstances rather than to the hormonal deficiency driving the neurological changes that underlie them.
DHEA restoration in Pakistani patients requires a clinical approach that is both comprehensive and precisely calibrated, because DHEA supplementation without addressing the metabolic and hormonal drivers of its depletion produces only temporary benefit, and DHEA supplementation without appropriate monitoring can produce androgenic side effects in women and oestrogen excess in men through peripheral conversion pathways. THE CHROMOSOME protocol approaches DHEA restoration primarily through addressing the adrenal biosynthetic environment, treating cortisol dysregulation, reducing the chronic metabolic stress driving cortisol prioritisation, restoring sleep architecture as the primary period of adrenal recovery, and reducing the visceral inflammatory load that directly impairs adrenal DHEA synthesis. Where direct DHEA supplementation is clinically indicated after these foundational interventions, it is incorporated at doses calibrated to the individual's age, sex, degree of deficiency, and conversion pathway monitoring, because appropriate restoration requires clinical judgment, not simply the prescription of a supplement.
Age related DHEA decline is a universal physiological process, DHEA production peaks in the mid twenties and declines progressively by approximately two percent annually through the adult decades, reaching approximately half the peak level by the mid fifties in healthy individuals without significant metabolic or stress burden. Pathological DHEA depletion, the pattern Dr. Zaar identifies consistently in Pakistani obesity patients, is an accelerated depletion driven by chronic cortisol excess, visceral inflammatory load, insulin resistance, sleep disruption, and the FTO associated adrenal biosynthetic vulnerability that produces DHEA levels in Pakistani patients in their forties that are equivalent to those of metabolically healthy individuals in their late sixties. The distinction matters clinically because pathological depletion is treatable, its drivers are identifiable and addressable, while age related decline is physiological and requires a different therapeutic approach. Measuring DHEA-S alongside cortisol and metabolic markers in every Pakistani patient presenting with unexplained fatigue, immune suppression, cognitive decline, or accelerated physical ageing is the only way to distinguish between the two, and making that distinction is what determines whether the patient receives appropriate treatment or inappropriate reassurance.